Phase 2Recruiting
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia
- Sponsor
- OHSU Knight Cancer Institute (Academic or other)
- Enrollment
- 102 planned
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndrome
- Interventions
- Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Cytarabine; Daunorubicin; Echocardiography Test; Fludarabine; Idarubicin; Multigated Acquisition Scan; Questionnaire Administration; Venetoclax; Device FLT3 Inhibitor
- Ages
- adults, older adults
- Registry
- NCT07228273
Full record on ClinicalTrials.gov
From the registry
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation…
Primary outcomes
- Percentage of participants achieving measurable residual disease negative composite complete remission (CRc-MRD-)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered